{"id":1246,"date":"2013-10-31T20:18:22","date_gmt":"2013-10-31T20:18:22","guid":{"rendered":"https:\/\/palladiumcapital.com\/?p=1246"},"modified":"2013-12-04T14:22:35","modified_gmt":"2013-12-04T14:22:35","slug":"palladium-completes-3500000-raise-for-biozone-pharmaceuticals-otcbbbzne","status":"publish","type":"post","link":"https:\/\/www.palladiumcapital.com\/palladium-completes-3500000-raise-for-biozone-pharmaceuticals-otcbbbzne\/","title":{"rendered":"Palladium Capital Advisors Completes $3,500,000 Raise for Biozone Pharmaceuticals (OTCBB:BZNE)"},"content":{"rendered":"<p><a href=\"https:\/\/palladiumcapital.com\/wp-content\/uploads\/2013\/12\/biozone-tombstone.jpg\"><img decoding=\"async\" loading=\"lazy\" class=\"size-medium wp-image-1250 alignright\" alt=\"biozone tombstone\" src=\"https:\/\/palladiumcapital.com\/wp-content\/uploads\/2013\/12\/biozone-tombstone-263x300.jpg\" width=\"263\" height=\"300\" srcset=\"https:\/\/www.palladiumcapital.com\/wp-content\/uploads\/2013\/12\/biozone-tombstone-263x300.jpg 263w, https:\/\/www.palladiumcapital.com\/wp-content\/uploads\/2013\/12\/biozone-tombstone.jpg 570w\" sizes=\"(max-width: 263px) 100vw, 263px\" \/><\/a><\/p>\n<p>&nbsp;<\/p>\n<p><span style=\"line-height: 1.714285714; font-size: 1rem;\">On October 25, 2013, Palladium Capital Advisors completed the sale of 3,500 shares of Series A Preferred Stock (&#8220;Series A&#8221;) of\u00a0Biozone Pharmaceuticals, Inc. (the &#8220;Company&#8221;) in a private placement offering to 22 accredited investors for total gross proceeds of $3,500,000. The Series A investors also were issued 7,000,000 10-year warrants exercisable at $0.50 per share (the &#8220;Warrants&#8221;). \u00a0For more information see <\/span><a style=\"line-height: 1.714285714; font-size: 1rem;\" href=\"http:\/\/biz.yahoo.com\/e\/131031\/bzne8-k.html\">here<\/a><span style=\"line-height: 1.714285714; font-size: 1rem;\">.<\/span><\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; On October 25, 2013, Palladium Capital Advisors completed the sale of 3,500 shares of Series A Preferred Stock (&#8220;Series A&#8221;) of\u00a0Biozone Pharmaceuticals, Inc. (the &#8220;Company&#8221;) in a private placement offering to 22 accredited investors for total gross proceeds of $3,500,000. The Series A investors also were issued 7,000,000 10-year warrants exercisable at $0.50 per [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"_links":{"self":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/posts\/1246"}],"collection":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/comments?post=1246"}],"version-history":[{"count":0,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/posts\/1246\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/media?parent=1246"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/categories?post=1246"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/tags?post=1246"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}